Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Viridian Therapeutics ( (VRDN) ) has shared an announcement.
At the Annual Meeting, Viridian Therapeutics‘ stockholders approved several key proposals, including an amendment to the 2016 Equity Incentive Plan, increasing available shares by 8,000,000. Additionally, all director nominees were elected, and KPMG LLP was ratified as the independent auditor for the fiscal year ending December 31, 2025. The approval of the 2025 Employee Stock Purchase Plan was also confirmed.
The most recent analyst rating on (VRDN) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Viridian Therapeutics stock, see the VRDN Stock Forecast page.
Spark’s Take on VRDN Stock
According to Spark, TipRanks’ AI Analyst, VRDN is a Neutral.
Viridian Therapeutics has strong technical momentum and promising corporate developments, notably the positive trial results and strategic board appointment. However, the company’s financial performance and valuation remain challenging, reflecting operational and profitability issues.
To see Spark’s full report on VRDN stock, click here.
More about Viridian Therapeutics
Average Trading Volume: 885,168
Technical Sentiment Signal: Sell
Current Market Cap: $1.2B
See more insights into VRDN stock on TipRanks’ Stock Analysis page.